Fibroblast growth factor-2 alters the effect of eroding polylactide-polyglycolide on osteogenesis in the bone chamber.
The effects of recombinant human fibroblast growth factor-2 (rhFGF-2) in the presence of eroding 50:50 poly(DL-lactide-co-glycolide) (PDLLG) on acute bone healing were studied in the optical bone chamber (BCI). BCIs were loaded with disks of PDLLG surrounded by one of four rhFGF-2 doses. Fifty-two female rabbit right tibias were implanted. Commencing the third week post implantation (W3) healing in the BCI compartment was observed weekly, using intravital microscopy, until W8. The doses were: unloaded, loaded with polymer only, and polymer plus 0.5, 1.0, and 10 microg rhFGF-2. Videotaped and photographed bone images were measured and analyzed using a frame-grabber digitizing system. Comparison with controls revealed that ossification rates were significantly above normal in rabbits loaded with polymer plus any of the rhFGF-2 doses. Comparison with polymer-only BCIs showed that PDLLG plus any of the three rhFGF-2 doses was linked with ossification rates significantly higher than baseline. The results indicated that FGF-2 in the dose range studied effectively can overcome the retarding effects of eroding polymer on ossification that has been reported by this laboratory. Interpretation of the retarding effects of the polymer disks, although consistent with previously studied washer-shaped devices of the same material, was complicated by a difference in erosion rate. This result supports the notion that erodible device geometry is a major factor in determining biocompatibility and must be considered in the design of carriers. Accordingly, programming of dose specificity for delivering a given polypeptide cytokine to a given host site must allow for the inhibitory effects of an eroding carrier and the influence of device geometry on these effects and erosion.
Winet
H
H
Bone Chamber Laboratory, J. Vernon Luck Sr. Research Center, Orthopaedic Hospital, Los Angeles, California 90007, USA. hwinet@hsc.usc.edu
Bao
J Y
JY
D000818:Animals; D001672:Biocompatible Materials; D001861:Bone Regeneration / Q000187:drug effects*; D004337:Drug Carriers; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D020007:Implants, Experimental; D010012:Osteogenesis / Q000187:drug effects*; D011091:Polyesters / Q000494:pharmacology*; D011100:Polyglycolic Acid / Q000494:pharmacology*; D011817:Rabbits
D001672:Biocompatible Materials; D004337:Drug Carriers; D011091:Polyesters; D016222:Fibroblast Growth Factor 2; D011100:Polyglycolic Acid; C033616:poly(lactide)